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Clinical Application of In Vitro 
Maturation of Oocytes
Xiaolin La, Jing Zhao and Zhihui Wang
Abstract
In vitro maturation (IVM) is a technique used to induce immature oocytes 
collected in different periods of embryonic growth. The rates vary for immature 
oocytes collected from different clinical sources to potentially develop into embryos 
and achieve live birth. As an effective treatment method, IVM can be used to treat 
patients with polycystic ovary syndrome (PCOS), ovarian hyperresponsiveness, 
and hyporesponsiveness, as well as to preserve the fertility of cancer patients. This 
technology has been used worldwide for the birth of thousands of healthy babies. 
The improvement in clinical IVM technology mainly focuses on the IVM medium 
and the optimization of the culture environment and operation process. At present, 
with the improvement in the in vitro fertilization (IVF) efficiency and culture sys-
tems, a natural cycle or mild stimulation may be more suitable for women receiving 
IVF treatments. A new treatment option was proposed to combine natural cycle/
mild stimulation IVF with IVM. In particular, the combination of mild stimulation 
IVF and IVM is not only expected to become a viable alternative to current standard 
treatments but may also become a potential option of first-line treatment.
Keywords: in vitro maturation (IVM), assisted reproductive technologies (ARTs), 
cytoplasmic maturation, antral follicles, granulosa cells
1. Introduction
In the 1960s, major milestones were achieved in in vitro maturation (IVM) of 
human oocytes, and in vitro fertilization (IVF) of IVM oocytes was also estab-
lished. Therefore, modern assisted reproductive technologies (ARTs) are based on 
IVM. Currently, the clinical application of IVM may be extended to treat patients 
with polycystic ovary syndrome (PCOS), ovarian hyperresponsiveness, and 
hyporesponsiveness, as well as to preserve the fertility of cancer patients [1]. In 
2013, the practice committees of the American Society for Reproductive Medicine 
(ASRM) and the Society for Assisted Reproductive Technology (SART) stated that 
the clinical pregnancy rate of IVM was still lower than that of conventional IVF, 
and hence IVM could not yet be considered the first treatment choice for all cases of 
female infertility [2].
The current standard protocol for ovulation induction in clinical practice 
involves intense stimulation with nonphysiological doses of gonadotropins to 
obtain an average of 10–15 or even dozens of mature oocytes per woman. Although 
the regimen of high-dose gonadotropin treatment may enable the retrieval of a 
larger number of oocytes, this approach can exert several short- and long-term 
adverse effects, including the risk of ovarian hyperstimulation syndrome (OHSS). 
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At present, with the improvement in the IVF efficiency and culture systems, a 
natural cycle or mild stimulation may be more suitable for women receiving IVF 
treatments. A previous study showed that natural cycle or mild stimulation IVF 
is more effective than conventional stimulation protocols in patients with a low 
functional ovarian reserve [3]. In contrast to the standard stimulation protocol, the 
mild stimulation protocol is a safer and more rational regimen that helps reduce the 
hormone dosage, lower treatment risks, and retrieve a small number of high-quality 
oocytes. Despite these theoretical advantages, the mild stimulation protocol has yet 
to become a mainstream treatment modality in the United States. With the devel-
opment of IVM technology, a modified protocol able to increase the success rates 
of natural cycle or mild stimulation IVF has been established. In this protocol, in 
addition to the retrieval of mature oocytes in naturally or mildly stimulated cycles, 
immature oocytes from small follicles are also retrieved for IVM, thereby increasing 
the total number of retrieved oocytes in a single treatment cycle and the clinical 
pregnancy rate. Data from previous clinical studies has shown that the combined 
use of natural cycle or mild stimulation IVF with IVM can expand the applicable 
scope of IVM technology to the treatment of various types of female infertility and 
has resulted in satisfactory clinical pregnancy rates and live birth rates [4, 5].
2. Mechanism of oocyte maturation
Cyclic adenosine monophosphate (cAMP) plays an important role in regulat-
ing the maturation of oocytes. The mural granulosa cells (MGC) located on the 
follicular wall contain natriuretic peptide precursor C (NPPC), while the cumulus 
cells around oocytes express natriuretic peptide receptor 2 (NPR2). Oocyte-derived 
paracrine factors can promote the activation of NPR2 in cumulus cells, while the 
NPPC in mural granulosa cells can bind to NPR2 receptors in cumulus cells to 
produce cyclic guanosine monophosphate (cGMP), which then enters into oocytes 
through gap junctions to inhibit the activity of phosphodiesterase (PDE3A), thereby 
maintaining a high level of cAMP in oocytes and the arrest of oocytes in the meiosis 
cycle. The activation of PDE3A by luteinizing hormone (LH) downregulates the 
level of cAMP in oocytes and induces the maturation of oocytes, thereby relieving 
the immature oocytes in the germinal vesicle (GV) stage or first meiotic metaphase 
(MII) from cell cycle arrest, so that they can complete the first meiosis and enter 
the second MII to develop into mature oocytes [6]. Zhang et al. [7] reported that 
estradiol can promote and maintain the expression of NPR2 in cumulus cells and 
participate in NPPC-mediated meiotic arrest of oocytes in vitro. These studies have 
opened up a new field of molecular mechanistic research on resuming the meiosis 
of oocytes, providing a theoretical basis for revealing the molecular mechanisms 
underlying the maturation of oocytes.
Studies have found that small molecule ribonucleotides (microRNAs) are also 
important for oocyte maturation. A certain number of dynamic and stable microRNAs 
were found in both mature oocytes and early-stage embryos, presumably contributing 
to the maturation of oocytes. Kim et al. [8, 9] reported that microRNAs may affect 
oocyte maturation by altering the gene expression and function of cumulus cells 
through cumulus cell interaction and paracrine secretion. Let-7 is one of the most 
abundant microRNAs in the ovary. Upregulation of Let-7c can increase the rate of 
oocyte maturation, suggesting that Let-7c may be involved in the information exchange 
between oocytes and surrounding mural granulosa cells. In addition, maturation-
promoting factor (MPF), cytostatic factor (CSF), oocyte maturation inhibitor (OMI), 
and mitogen-activated protein kinase (MAPK) are involved in oocyte maturation and 
division [7]. The mechanisms underlying oocyte maturation awaits further studies.
3Clinical Application of In Vitro Maturation of Oocytes
DOI: http://dx.doi.org/10.5772/intechopen.87773
3. Definition of oocyte IVM
The biological definition of oocyte IVM is to remove immature oocytes in the 
GV stage from antral follicles and culture them in a suitable culture system, so that 
these immature oocytes can mature to MII stage in vitro. However, the clinical 
definition of IVM technology for immature human oocytes is completely differ-
ent from its biological definition. The differences include the different sources of 
immature oocytes, the different protocols used to induce ovulation, and the dif-
ferent time of oocyte retrieval. These factors may lead to the situation where the 
immature oocytes retrieved clinically are not in the GV stage. The use of human 
chorionic gonadotropin (hCG) to induce ovulation prior to clinical retrieval of 
oocytes may lead to the initiation of endogenous oocyte maturation, and hence 
some of the retrieved immature oocytes may have undergone germinal vesicle 
breakdown (GVBD) or entered the MI stage. Although immature oocytes in the MI 
stage have initiated the process of in vivo maturation, they still need to participate 
in the procedure of in vitro culture and maturation. Therefore, the definition of 
clinical IVM treatment should include the in vitro culture of immature oocytes in 
the GV and MI stages.
A recent point of view proposed to give the clinical definition of IVM of imma-
ture oocytes based on the diameter of follicles when the oocytes are retrieved [10]. 
However, this definition is not completely scientific, since the meiotic state of 
oocytes cannot be completely determined according to the size of follicles during 
the stimulation cycle [11, 12]. In addition, for immature oocytes collected from 
different clinical sources, their maturation rate and the rates to potentially develop 
into embryos and achieve live birth are different. Therefore, for clinical definition 
and research of IVM, attention should be paid to the effect of different sources of 
immature oocytes on the efficiency of IVM.
4. Factors affecting the in vitro maturation of oocytes
4.1 Effect of culture time on in vitro maturation of oocytes
Maturation of oocytes includes the nuclear and cytoplasmic maturation of 
oocytes. Nuclear maturation refers to the rupture of the germinal vesicle, separation 
of homologous chromosomes, appearance of the perivitelline space, and discharge 
of the first polar body. Cytoplasmic maturation refers to the completion of protein 
phosphorylation and dephosphorylation as well as the rearrangement of organelles 
in oocytes. Only the oocytes whose nucleus and cytoplasm are matured simultane-
ously can have adequate fertility and the potential for embryo development. Studies 
have found that most oocytes cultured in vitro can reach maturity within 24–48 h. 
The length of in vitro culture can affect the developmental potential of the embryo. 
The rate of nuclear maturation in oocytes cultured for 48 h in vitro is significantly 
higher than that for 24 h, but the rate of cytoplasmic maturation in oocytes cultured 
for 48 h is not significantly different from that for 24 h. Excessive culture time 
leads to the aging of oocytes and an increased level of associated genetic risks. 
When the culture time is too short, the maturation of cytoplasm and nucleus is not 
synchronized and will affect the subsequent development potential of the embryo. 
Wrenzycki et al. [13] found that oocytes only possess the ability to mature in the 
final stage of development. Therefore, adequate extension of IVM time can promote 
the necessary process of oocyte maturation, increase the rate of nuclear maturation 
in immature oocytes, and significantly improve in vitro developmental potential of 
oocytes and the rate of high-quality embryos.
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4.2 Effects of hormones on in vitro maturation of oocytes
Gonadotropin can promote the expansion of cumulus cells and stimulate the 
maturation of the nucleus and cytoplasm of oocytes, thus facilitating the formation 
of embryos and blastocysts in the cleavage stage and playing an important role in 
follicular development [14]. The addition of follicle-stimulating hormone to the 
culture medium for oocyte maturation can promote the cytoplasmic maturation 
of oocytes. Some scholars believe that the effect of follicle-stimulating hormone 
is related to its concentration. When the concentration is 5 g/mL, a relatively high 
cleavage rate (79.1%) and blastocyst rate (16.1%) can be obtained [15]. The addition 
of LH or human chorionic gonadotropin to the IVM culture medium may promote 
protein synthesis, enhance oocyte metabolism, and facilitate oocyte maturation. 
The concentration of estradiol (E2) in the human body increases with an increas-
ing volume of follicles. In addition, estradiol is involved in maintaining the meiotic 
arrest of oocytes and can promote the cytoplasmic maturation of oocytes. During 
in vitro culture of oocytes, nuclear maturation is faster than cytoplasmic matura-
tion. Therefore, the addition of E2 to the culture medium helps synchronize the 
development of the nucleus and cytoplasm in oocytes.
4.3 Effect of antioxidant addition on in vitro maturation of oocytes
As a hydrophobic activator, forskolin (FSK) can increase the activity of adenyl-
ate cyclase in mammalian cells and the level of intracellular cAMP. By adding FSK 
to an IVM culture medium, Ezoe et al. [16] significantly improved the develop-
mental capacity of oocytes in the GV stage. By adding FSK to the culture medium, 
Zeng et al. [17] promoted the synchronization of nuclear and cytoplasmic matura-
tion and increased the rates of maturation, cleavage, and high-quality embryos. 
During IVM, the presence of oxidative stress may block oocyte maturation, lead 
to abnormal gene expression, and impair the cytoplasmic and nuclear develop-
ment of oocytes, thereby resulting in the failure to obtain high-quality oocytes and 
decreasing the fertility and developmental capacity. The addition of antioxidants 
to the culture medium can reduce the damage caused by oxidative stress. By add-
ing a-lipoic acid to the culture medium, Zavareh et al. [18] reduced the content 
of active oxygen, increased the total antioxidation capacity, and promoted the 
nuclear and cytoplasmic maturation of oocytes in vitro. The results of Mokhber 
et al. [19, 20] showed that an appropriate concentration of a natural antioxidant, 
crocin (100 g/mL), and aqueous extract of saffron (40 g/mL) can increase the 
concentration of glutathione (GSH), protect oocytes, and significantly increase 
IVM rate and fertility rate.
4.4  Effect of co-culture with mural granulosa cells on in vitro maturation of 
oocytes
Together with cumulus cells and follicular fluid, MGC form an in vivo environ-
ment for oocyte maturation. Co-culture with MGC can increase the rate of nuclear 
and cytoplasmic maturation of immature oocytes. Studies have shown that co- 
culture with parietal MGC can improve the nuclear maturation of naked oocytes, 
slow down the nuclear maturation of naked oocytes, increase the content of gluta-
thione in naked oocytes, reduce the activity of glucose-6-phosphate dehydrogenase 
in naked oocytes, increase the rate of cytoplasmic maturation, and facilitate the 
simultaneous development of the nucleus and cytoplasm of oocytes [21]. Although 
immature oocytes detached of MGC can still mature, they cannot undergo normal 
5Clinical Application of In Vitro Maturation of Oocytes
DOI: http://dx.doi.org/10.5772/intechopen.87773
fertilization and development because the cytoplasm is not synchronously matured 
[22]. The addition of a certain amount of MGC to the culture medium can delay the 
nuclear maturation of oocytes, so that the maturation of the nucleus and cytoplasm 
becomes more synchronized. However, there is currently no uniform standard for 
the amount of MGC addition. Choi et al. [23] significantly increased the develop-
ment potential of embryos by co-culturing the oocyte-corona-cumulus complex 
with naked oocytes at a 1:5 ratio.
4.5  Effect of co-culture with oviductal epithelial cells on in vitro maturation of 
oocytes
Some scholars have pointed out that the maturation of oocytes is completed in 
the fallopian tube, and hence some components of the fallopian tube may affect the 
maturation process of oocytes. Human tubal fluid (HTF) has been used to culture 
oocytes. Shirazi et al. [24] co-cultured ovine oocytes with oviductal epithelial cells 
(OECs) and conducted IVF, resulting in higher cleavage and blastocyst rates.
4.6  Effect of co-culture with mesenchymal stem cells on in vitro maturation of 
oocytes
In addition to the potential of self-renewal and multidirectional differentiation, 
mesenchymal stem cells (MSCs) can also secrete a variety of cytokines and growth 
factors, and some biologically active factors can enhance the in vitro maturation of 
oocytes and subsequent developmental potential of embryos. By adding MSCs to 
a culture medium, Ling et al. [25] significantly increased the maturation rate and 
rate of blastocyst formation of immature murine oocytes. It can be seen that the 
co-culture system with MSCs can promote the simultaneous development of the 
nucleus and cytoplasm of murine oocytes.
5. Sources of immature oocytes
5.1 Oocyte retrieval from cesarean section or gynecological surgery
Immature oocytes retrieved from the ovarian cortex during cesarean section can 
be cultured in vitro to achieve maturation, fertilization, and healthy progeny. The 
mature oocytes cultured in this way are expected to be used as the source of oocytes 
to preserve female fertility [26]. At present, few studies have investigated the 
approach to obtain immature oocytes during cesarean section for in vitro culture, 
and hence more studies are needed to prove the safety and effectiveness of imma-
ture oocytes obtained from cesarean section.
In addition to cesarean section, immature oocytes can also be obtained via gyne-
cological surgery in the follicular phase or luteal phase. The number of retrieved 
oocytes is mainly related to the age, pathological status, and stage of the menstrual 
cycle of the patient. Clinical studies have confirmed that oocyte retrieval carried 
out at different stages of the menstrual cycle does not affect the rate of in vitro 
maturation and the rate of fertilization of oocytes, suggesting that IVM technique 
can be used to preserve fertility in cancer patients during the follicular phase or 
luteal phase [27]. Therefore, for cancer patients who lack sufficient time for treat-
ment and are unable to use hormone to induce ovulation, immature oocytes can be 
retrieved before chemotherapy to carry out IVM and vitrification to maximize the 
preservation of fertility.
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5.2 PCOS patients
A large number of antral follicles are present in the ovary of infertile women 
with anovulatory PCOS. These antral follicles are more sensitive to gonadotropins, 
and hence the risk of OHSS is increased when hormones are used to induce ovula-
tion. Therefore, for PCOS patients, immature oocytes can be retrieved from antral 
follicle for in vitro maturation [28]. The use of hCG at 36 h before oocyte retrieval 
in PCOS patients can promote the resumption of meiosis of immature oocytes and 
their in vitro maturation, improving the rate of pregnancy and clinical outcomes 
[29]. The use of small doses of gonadotropin before the retrieval of immature 
oocytes from PCOS patients is also beneficial to improve the maturation potential 
of oocytes, increasing the rate of embryo implantation and clinical pregnancy. In 
addition, IVM techniques can also be considered for some PCOS patients with no or 
low response to hormones [30].
5.3 Women with normal ovaries and menstrual cycles
Based on the advantages of low hormone dosage, low cost, and simple treatment 
process, IVM has been gradually applied to the treatment of infertile women with 
normal ovaries and regular menstrual cycles. However, it remains controversial 
as whether the use of hCG is required in the IVM treatment of this type of patient 
prior to oocyte retrieval. It should be noted that the hCG trigger exerts different 
effects on normal ovaries and PCOS patients. In the IVM treatment cycle of PCOS 
patients, dominant follicles are barely visible in the ovary, but MI-stage oocytes can 
be retrieved from small follicles after hCG-induced ovulation. However, after the 
hCG trigger is used in the normal ovary during the follicular phase, most oocytes 
retrieved from small follicles are oocytes in the GV stage. There is currently no evi-
dence suggesting that the hCG trigger exerts a significant effect on the pregnancy 
rate, live birth rate, or abortion rate in the IVM of immature oocytes obtained 
from normal ovaries [31]. However, the accuracy of these findings is limited by the 
small number of samples. Therefore, a well-designed, randomized, and controlled 
clinical trial is needed to further confirm the optimal dosage and timing of hCG 
administration.
6. IVM culture system
6.1 Improvement of IVM media
The in vitro maturation of oocytes is mainly affected by culture conditions. At 
present, the common media used for the IVM of immature human oocytes include 
TCM-199 medium, Ham’s F10 medium, and Chang’s medium. In addition, serum, 
gonadotropin [follicle-stimulating hormone and luteinizing hormone], growth fac-
tors, and steroids can be added in a basal medium to produce a complex medium. At 
present, commercial IVM media have been widely used. However, no breakthrough 
has been made in the research on improving the quality of oocytes by improving 
the IVM medium. In recent years, research and application of antioxidants and 
growth-promoting factors have promoted the advancement of this technology to 
some extent. In addition, using cell cycle regulators or inhibitors of mitotic spindle 
formation, the synchronization of nuclear and cytoplasmic maturation of immature 
oocytes can be achieved by inhibiting GVBD, thereby increasing the blastocyst rate 
and live birth rate in animal models [32]. However, the safety and efficacy of this 
method in human oocytes should be further verified.
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6.2 Optimization of IVM culture environment and process
The culture environment, equipment, and related operations in the IVM system 
may affect the in vitro maturation and embryo development of immature oocytes. 
Therefore, the optimization of the embryo culture environment and process of 
in vitro operation will help to maintain the potential of embryonic development 
[33, 34]. The three-dimensional culture system can support the development of fol-
licles by using biological materials to maintain cell-to-cell information exchange. In 
addition, mature oocytes can be obtained by using a three-dimensional culture sys-
tem in the in vitro culture of anterior follicles of nonhuman primates [35], although 
no reports are available regarding the use of a three-dimensional culture system in 
the in vitro culture of immature human oocytes. A past study has used microreac-
tors to form three-dimensional bioreactors to support the growth of different types 
of cells [36]. Consisting of a drop of liquid encapsulated by hydrophobic powder 
particles, this system can provide a suitable microenvironment for in vitro matura-
tion of oocytes. In addition, the development of microfluidic technology will exert 
an important impact in the field of human gametes and preimplantation embryo 
development and will have potential applications in the field of ART. This technol-
ogy enables the creation of microfluidic models mimicking the “menstrual cycle of 
women” [37]. These models include interconnected 3D models of different tissues, 
such as 3D models of the ovaries, fallopian tubes, uterus, cervix, and vagina, in 
the female reproductive system and the endocrine cycle between various organ 
modules. The mechanical and biochemical properties of microfluidic systems still 
require intensive research before these systems can be applied to clinical applica-
tions in areas such as IVM of immature human oocytes.
7. Clinical application and safety of IVM
At present, the in vitro maturation rate of immature human oocytes can reach 
70%, but the developmental potential of mature oocytes obtained in vitro is 
still lower than that of mature oocytes obtained in vivo. In addition, the rate of 
blastocyst development and the rate of implantation are relatively low after the 
fertilization of IVM oocytes. The main reason of such discrepancy may be related 
to non-synchronized nuclear and cytoplasmic maturation during IVM. With the 
further development in the basic and clinical research of IVM, the in-depth study 
on the mechanisms of oocyte maturation and mastery of key factors involved in 
oocyte maturation will contribute to the improvement and optimization of clinical 
IVM technology.
The results of current research showed that human oocytes matured in vivo or 
in vitro display no significant differences in terms of their spindle morphology, 
organelle distribution, cortical particle distribution, and mitochondrial morphol-
ogy [38, 39]. By observing embryos dynamically using time-lapse videos, it was 
confirmed that oocytes matured in vivo or in vitro showed no significant differ-
ences in terms of the morphological dynamics observed during the early develop-
ment of embryos derived from these oocytes [40]. Another study has also shown 
that the oocytes matured in vitro and in vivo are different in terms of their organ-
elle function, distribution, and gene expression [41]. The different experimental 
conclusions mentioned above may be caused by different sources and quality of 
oocytes used in these studies. Therefore, attention should be paid to clarify the IVM 
efficiency of oocytes retrieved from different sources, so as to reasonably evaluate 
the safety of IVM. In terms of epigenetics, a study has reported that IVM exerts 
no significant effect on the methylation level of maternal imprinted genes, such as 
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LIT1, SNRPN, PEG3, and GTL2, in human oocytes [42]. After an imprinted gene 
examination was carried out for infant chorionic cells and cord blood obtained 
from IVM and a standard stimulation protocol, no significant difference was 
observed between the two methods [43, 44]. Currently, the follow-up of IVM-aided 
pregnancies shows that the IVM technique does not increase the risk of pregnancy, 
the rate of maternal complications, and the rate of neonatal abnormalities [45, 46]. 
However, due to a small sample size and the lack of in-depth study on epigenetics, 
the clinical application and safety of IVM still require investigations of large sample 
sizes to reach a definitive conclusion regarding the safety of IVM in terms of 
epigenetics.
At present, more than 5000 IVM babies have been born worldwide, and the rate 
of clinical pregnancy among PCOS patients undergoing IVM treatment can reach 
about 35–40% [47]. IVM has been extended from the basic research to the treat-
ment of patients with PCOS, ovarian hyperresponsiveness and hyporesponsiveness, 
as well as cancer patients to preserve the fertility. Therefore, IVM has a prospect of 
broad applications.
8. Conclusion
At present, the application scope of IVM technology can be extended to patients 
with various causes of infertility. In addition, the IVM technology is associated with 
acceptable pregnancy and live birth rates. Although IVM has been used as an effec-
tive treatment and achieved significant outcomes with thousands of healthy IVM 
babies having been delivered, IVM is still considered as an experimental technique 
by the society. With the development of IVM technology, the combination of 
natural cycle IVF with the IVM of immature oocytes can be used as an attractive 
regimen to promote IVM treatment. More infertile women can benefit from such 
approaches if the treatment process is simplified by mild stimulation, especially 
when the difficulty to obtain immature oocytes is reduced. Therefore, the combina-
tion of mild stimulation IVF and IVM treatment can become a viable alternative 
to current standard treatments. With the accumulation of more experience and 
results, it will be further demonstrated that the combination of mild stimulation 
IVF and IVM is not only a viable alternative to current standard treatments but may 
also become a potential option of first-line treatment.
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